Protein-free fed-batch culture of non-GS NSO cell lines for production of recombinant antibodies

Biotechnology and Bioengineering

Volumn 96, Issue 2, 2007, Pages 281-293

  Burky, John E ^a   Wesson, Mark C ^a   Young, Amy ^a   Farnsworth, Sharyn ^a   Dionne, Ben ^a   Zhu, Ying ^a   Hartman, Taymar E ^a   Qu, Limin ^a   Zhou, Weichang ^a   Sauer, Paul W ^a  

^a PDL BioPharma Inc   (United States)

Author keywords

Fed batch culture process platform; Humanized antibodies; Lactate consumption; NS0 host cell line; Protein free

Indexed keywords

ANTIBODIES; BIOREACTORS; CONCENTRATION (PROCESS); COST EFFECTIVENESS; OPTIMIZATION;

CULTURE PROCESS PLATFORMS; LACTATE CONSUMPTION; VOLUMETRIC PRODUCTIVITY;

CELL CULTURE;

GLUCOSE; LACTIC ACID; RECOMBINANT ANTIBODY;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; BIOREACTOR; CELL DEATH; CELL LINE; CULTURE MEDIUM; METABOLISM; NONHUMAN; PROTEIN RESTRICTION; REPRODUCIBILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE; CHOLESTEROL; HUMANS; MICE; RECOMBINANT PROTEINS;

EID: 33846899672     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21060     Document Type: Article

References (37)

1. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT. 1992. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable marker. Biotechnology 10:169-175.
2. Bibila TA, Robinson DK. 1995. In pursuit of the optimal fed-batch process for monoclonal antibody production. Biotechnol Prog 11:1-13.
3. Bibila T, Ranucci C, Glazomitsky K, Buckland B, Aunins J. 1994. Investigation of NS0 cell metabolic behavior in monoclonal antibody producing clones. Ann NY Acad Sci 745:277-284.
4. Birch JR, Boraston RC, Metcalfe H, Brown ME, Bebbington CR, Field RP. 1994. Selecting and designing cell lines for improved physiological characteristics. Cytotechnology 15(1-3):11-16.
5. Brand KA, Hermfisse U. 1997. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. Faseb J 11:388-395.
6. Brooks GA. 1985. Lactate: Glycolytic product and oxidative substrate during sustained exercise in mammals- the 'lactate shuttle.' In: Gilles R, editor. Comparative physiology and biochemistry: Current topics and trends. Berlin: Springer. p 208-218.
7. Brooks GA. 2000. Intra- and extra-cellular lactate shuttles. Med Sci Sports Exerc 32(4):790-799.
8. Cain SJ, Chau PC. 1998. Transition probability cell cycle model with product formation. Biotechnol Bioeng 58(4):387-399.
9. Chadd HE, Chamow SM. 2001. Therapeutic antibody expression technology. Curr Opin Biotechnol 12(2):188-194.
10. Dempsey J, Ruddock S, Osborne M, Ridley A, Sturt S, Field R. 2003. Improved fermentation processes for NS0 cell lines expressing human antibodies and glutamine synthetase. Biotechnol Prog 19(1):175-178.
11. deZengotita VM, Miller WM, Aunins JG, Zhou W. 2000. Phosphate feeding improves high-cell-concentration NS0 myeloma culture performance for monoclonal antibody production. Biotechnol Bioeng 69(5):566-576.
12. DiStefano DJ, Mark GE, Robinson DK. 1996. Feeding of nutrients delays apoptotic death in fed-batch cultures of recombinant NS0 myeloma cells. Biotechnol Lett 18(9):1067-1072.
13. Gladden LB. 2001. Lactic acid: New roles in a new millennium. PNAS 98(2):395-397.
14. Gladden LB. 2004. Lactate metabolism: A new paradigm for the third millennium. J Physiol 558(Pt 1):5-30.
15. Gorfien S, Paul B, Walowitz J, Keem R, Biddle W, Jayme D. 2000. Growth of NS0 cells in protein-free, chemically defined medium. Biotechnol Prog 16(5):682-687.
16. Hartman T, Sar N, Genereux K, Barritt D, He A, Burky JE, Wesson MC, Tsurushita N, Zhou W, Sauer PW. 2006. Derivation and Characterization of Cholesterol-Independent non-GS NS0 Cell Lines for Production of Recombinant Antibodies. Biotechnol Bioeng. 96:294-306.
17. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176(5):1215-1224.
18. Kawamoto T, Sato JD, Le A, McClure DB, Sato GH. 1983. Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of NS-1 hybridomas. Anal Biochem 130(2):445-453.
19. Keen MJ. 1995. Adaptation of cholesterol-requiring NS0 mouse myeloma cells to high density growth in a fully defined protein-free and cholesterol-free culture medium. Cytotechnology 17:203-211.
20. Kurokawa H, park YS, Iigima S, Kobayashi T. 1994. Growth characteristics in fed-batch culture of hybridoma cells with control of glucose and glutamine concentrations. Biotechnol Bioeng 44:95-103.
21. Ljunggren J, Haeggstroem L. 1994. Catabolic control of hybridoma cells by glucose and glutamine limited fed batch cultures. Biotechnol Bioeng 44:808-818.
22. Luan YT, Mutharasan R, Magee WE. 1987. Strategies to extend longevity of hybridomas in culture and promote yield of monoclonal antibodies. Biotechnol Lett 9(10):691-696.
23. McComb RB. 1983. The measurement of lactate dehydrogenase. In: Homberger HA, editor. Clinical and analytical concepts in enzymology. Skokie, IL: College of American Pathologists. p 157-171.
24. Merten OW. 1999. Safety issues of animal products used in serum-free media. Dev Biol Stand 99:167-180.
25. Physician's Desk Reference. 2005. 59th ed. Montvale, NJ: Thomson PDR. p 3344-3347.
26. Ryu JS, Lee GM. 1999. Application of hypoosmolar medium to fed-batch culture of hybridoma cells for improvement of culture longevity. Biotechnol Bioeng 62(1):120-123.
27. Sauer PW, Burky JE, Wesson MC, Sternard HD, Qu L. 2000. A high-yielding, generic fed-batch cell culture process for production of recombinant antibodies. Biotechnol Bioeng 67(5):585-597.
28. Suzuki E, Ollis DF. 1990. Enhanced antibody production at slowed growth rates: Experimental demonstration and a simple structured model. Biotechnol Prog 6(3):231-236.
29. Warburg O, Poesener K, Negelein E. 1924. Über den Stoffwechsel der Carcinomzelle. Biochemische Zeitschrift 152:309-344.
30. Werner RG. 2004. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol 113(1-3):171-182.
31. Whitford W. 2003. NS0 serum-free culture and applications, BioProcess Int 1(12):36-47.
32. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):1393-1398.
33. Xie L, Wang DIC. 1993. Fed-batch cultivation of animal cells using different medium design concepts and feeding strategies. Biotechnol Bioeng 43:1175-1189.
34. Yoo EM, Chintalacharuvu KR, Penichet ML, Morrison SL. 2002. Myeloma expression systems. J Immunol Methods 261(1-2):1-20.
35. Zhang L, Shen H, Zhang Y. 2004. Fed-batch culture of hybridoma cells in serum-free medium using an optimized feeding strategy. J Chem Technol Biotechnol 79:171-181.
36. Zhou W, Rehm J, Hu W-S. 1995. High viable cell concentration fed-batch cultures of hybridoma cells through on-line nutrient feeding. Biotechnol Bioeng 46:579-587.
37. Zhou W, Chen C, Buckland B, Aunins JG. 1997. Fed-batch culture of recombinant NS0 myeloma cells with high monoclonal antibody production. Biotechnol Bioeng 55:783-792.